Treatment paradigms for MDS are changing.
Our most recent syndicated survey will tell you how and why.
Patients with Myelodysplastic syndrome (MDS), particularly high-risk patients (based on the revised International Prognostic Scoring System IPSS-R), face very poor outcomes, where median survival has been reported as being just 9 months. In addition to poor outcomes, many MDS patients will see their disease transform into AML, where the risk of AML increases with a worsening prognostic risk score. In recent years, a wave of new product developments and treatment options for MDS patients of all risk groups were introduced which are expected to change the treatment paradigm and outcomes for patients.
Capitalizing on our unique expertise as pioneers of patient chart-based research, we offer subscriptions to our real-world data providing insights and the latest understanding of changing paradigms in the treatment of MDS across all types. Importantly, as the classification system changes, MDSsyndiTrack also captures the physician perceptual classification vs the real-world classification (% myeloblasts) of patients with MDS vs AML-MRC.
Example of a recent wave:
- data collected in Q4 22 in Germany, France, Italy, Spain , USA, Japan, and China
- Over 500 Onco-hematologists
- over 3,000 real-world MDS patient charts
- Back data available for the UK, Germany, France, Italy, Spain,
Canada, Austria, Belgium, Netherlands, Sweden, Brazil